World News | South African Pharma Firm Signs Deal with Johnson & Johnson to Produce COVID-19 Vaccine

Cape Town [South Africa], November 2 (ANI/Sputnik): South African pharmaceutical company Aspen Pharmacare has signed a deal with two subsidiaries of Johnson & Johnson to begin the manufacture of the multinational firm's candidate vaccine against the coronavirus disease, the South African company said on Monday.

"Aspen is pleased to announce that one of its wholly-owned South African subsidiaries, Pharmacare Limited (which trades as "Aspen Pharmacare"), has entered into a preliminary agreement with Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica NV, two of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the technical transfer and proposed commercial manufacture of their COVID-19 vaccine candidate, Ad26.COV2-S," Aspen said in a press release.

Also Read | Priyanca Radhakrishnan, Native of Kerala, Becomes The First Indian to Be Sworn in As Minister in New Zealand PM Jacinda Ardern’s Cabinet.

As part of the deal, Aspen will ensure production capacity at its sterile facility based in the South African city of Port Elizabeth, the company said, adding that it has invested more than USD 184 million in the facility for the manufacture and packaging of drugs and vaccines.

"We have invested globally in our sterile capability and are determined to play a role in the manufacture of vaccines to add to our proud track record of making contributions to humanity in times of global pandemics," Stephen Saad, Aspen Group's chief executive, said in the press release.

Also Read | US Elections 2020 Candidate Profile: Know All About Kamala Harris, The Democratic Vice Presidential Candidate, And Her Husband Douglas Emhoff.

Phase three trials of Johnson & Johnson's candidate vaccine against COVID-19 were temporarily paused in October after a participant became ill. The multinational said in a press release on October 23 that there was no evidence linking the inoculation to the illness, adding that it was preparing to resume the clinical trials.

Johnson & Johnson is hoping to make its candidate vaccine available in early 2021 if proven safe and effective. (ANI/Sputnik)

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)